Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ViewRay stock

Own ViewRay stock in just a few minutes.

Fact checked

ViewRay, Inc is a medical devices business based in the US. ViewRay shares (VRAY) are listed on the NASDAQ and all prices are listed in US Dollars. ViewRay employs 309 staff and has a trailing 12-month revenue of around USD$55 million.

How to buy shares in ViewRay

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for ViewRay. Find the stock by name or ticker symbol: VRAY. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ViewRay reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of ViewRay, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of ViewRay. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

ViewRay share price

Use our graph to track the performance of VRAY stocks over time.

ViewRay shares at a glance

Information last updated 2021-01-20.
52-week rangeUSD$1.1055 - USD$7.36
50-day moving average USD$4.5883
200-day moving average USD$3.387
Wall St. target priceUSD$5.88
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.213

Buy ViewRay shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ViewRay stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ViewRay financials

Revenue TTM USD$55 million
Gross profit TTM USD$2.4 million
Return on assets TTM -26.3%
Return on equity TTM -90.39%
Profit margin -212.65%
Book value $1.021
Market capitalisation USD$808.2 million

TTM: trailing 12 months

Shorting ViewRay shares

There are currently 13.3 million ViewRay shares held short by investors – that's known as ViewRay's "short interest". This figure is 2.3% down from 13.6 million last month.

There are a few different ways that this level of interest in shorting ViewRay shares can be evaluated.

ViewRay's "short interest ratio" (SIR)

ViewRay's "short interest ratio" (SIR) is the quantity of ViewRay shares currently shorted divided by the average quantity of ViewRay shares traded daily (recently around 1.3 million). ViewRay's SIR currently stands at 10.4. In other words for every 100,000 ViewRay shares traded daily on the market, roughly 10400 shares are currently held short.

However ViewRay's short interest can also be evaluated against the total number of ViewRay shares, or, against the total number of tradable ViewRay shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ViewRay's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 ViewRay shares in existence, roughly 90 shares are currently held short) or 0.1312% of the tradable shares (for every 100,000 tradable ViewRay shares, roughly 131 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against ViewRay.

Find out more about how you can short ViewRay stock.

ViewRay share dividends

We're not expecting ViewRay to pay a dividend over the next 12 months.

Have ViewRay's shares ever split?

ViewRay's shares were split on 8 July 2015.

ViewRay share price volatility

Over the last 12 months, ViewRay's shares have ranged in value from as little as $1.1055 up to $7.36. A popular way to gauge a stock's volatility is its "beta".

VRAY.US volatility(beta: 1.03)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ViewRay's is 1.0341. This would suggest that ViewRay's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

ViewRay overview

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site